Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Subscribe Listen in podnod RSS feed Show website

413 episodes
Updated Yesterday

Episodes413

Newest first

Dec 15, 2025 · 1 min
Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.
Dec 11, 2025 · 1 min
Pharmaceutical Executive Daily: FDA's Approval of Waskyra
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.
Dec 10, 2025 · 1 min
Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals
In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration targeting atopic diseases, and new insights reveal how payers are shaping expectations for Phase III trial design.
Dec 9, 2025 · 1 min
Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions
In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.
Dec 8, 2025 · 1 min
Pharmaceutical Executive Daily: FDA Approves Breyanzi
In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a head-to-head Phase III trial against Imbruvica for CLL/SLL, and new analyses highlight how health systems are strengthening partnerships to support cell and gene therapy commercialization.
Dec 5, 2025 · 1 min
Pharmaceutical Executive Daily: Mark Cuban's Push for Generic Drug Fee Waivers
In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory standards, Mark Cuban urges federal officials to waive fees to boost generic drug competition, and a new report reveals patients are increasingly avoiding care due to rising healthcare costs.
Dec 4, 2025 · 1 min
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
In today’s Pharmaceutical Executive Daily, the FDA appoints Tracy Beth Høeg as acting CDER director, health systems explore new commercialization partnerships for cell and gene therapies, and Aidoc submits a breakthrough-designated multi-triage AI device for FDA approval.
Dec 3, 2025 · 1 min
Pharmaceutical Executive Daily: FDA's Agentic AI Deployment
In today’s Pharmaceutical Executive Daily, Regeneron launches a $150 million gene editing collaboration with Tessera Therapeutics, the FDA begins agency-wide deployment of new agentic AI tools, and a new report suggests Richard Pazdur is stepping down as director of CDER.
Dec 2, 2025 · 1 min
Pharmaceutical Executive Daily: Lilly Reduces the Price of Zepbound
In today’s Pharmaceutical Executive Daily, Eli Lilly reduces the price of Zepbound single-dose vials for self-pay patients, a new report claims the FDA is planning changes to its vaccine approval process following assertions of COVID vaccine–related deaths, and Korea and Australia reorient their pharma launch strategies toward broader regional market opportunities.
Dec 1, 2025 · 1 min
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, the US and UK agree to eliminate tariffs on pharmaceutical products, and CMS publishes major price cuts for 15 high-cost Medicare drugs under the latest IRA negotiation round.
Nov 26, 2025 · 1 min
Pharmaceutical Executive Daily: Novartis Cuts 550 Jobs
In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular atrophy, and industry experts weigh in on how next-generation CDMOs are evolving to meet rapid market change.
Nov 25, 2025 · 2 min
Pharmaceutical Executive Daily: Moderna's $1.5 Billion Loan
In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes out a $1.5 billion loan to support its long-term growth plan, and Medicare moves closer to releasing negotiated prices for 15 widely used, high-cost medicines.
Nov 24, 2025 · 2 min
Pharmaceutical Executive Daily: Tesaro and AnaptysBio's Legal Battle
In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship Pioneering and Valo Health announce major new collaborations, and why integrated direct-to-patient drug distribution is becoming a strategic imperative.
Nov 21, 2025 · 1 min
Pharmaceutical Executive Daily: Novartis' North Carolina Manufacturing Hub
In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manufacturing hub in North Carolina, and the FDA is rolling out a wide batch of drug approvals.
Nov 20, 2025 · 1 min
Pharmaceutical Executive Daily: Moderna's $140 Million Manufacturing Investment
In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new research collaborations under the LTZ Fleming Initiative, and the FDA commissioner highlights how early and late movers can benefit from the National Priority Voucher program.
Nov 19, 2025 · 1 min
Pharmaceutical Executive Daily: FDA's Approval of Epkinly
In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.
Nov 18, 2025 · 1 min
Pharmaceutical Executive Daily: Novo Nordisk's Leadership Restructure
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli Lilly, and the FDA launches its new Plausible Mechanism Pathway to accelerate drug development.
Nov 13, 2025 · 1 min
Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval
In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.
Nov 13, 2025 · 2 min
Pharmaceutical Executive Daily: Dr. Richard Pazdur Appointed as Director CDER
In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, Pfizer strengthens focus through strategic partnerships and spin-offs, and CMS launches a new initiative to reduce Medicaid drug costs.
Nov 12, 2025 · 2 min
Pharmaceutical Executive Daily: AstraZeneca Becomes UK's Largest Stock
In today’s Pharmaceutical Executive Daily, AstraZeneca surpasses Shell to become the UK’s largest listed company, Basel intensifies efforts to attract international pharma executives, and HHS removes misleading safety warnings from menopausal hormone therapy labels.